NASDAQ:SLXP - Salix Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$172.81 0.00 (0.00 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$172.81
Today's RangeN/A
52-Week Range$86.00 - $172.98
VolumeN/A
Average Volume4.96 million shs
Market Capitalization$10.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Salix Pharmaceuticals logoSalix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive SLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLXP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SLXP
CUSIP79543510
Phone+1-919-8621000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-2,134.34%
Return on Equity-305.24%
Return on Assets-25.83%

Miscellaneous

EmployeesN/A
Outstanding Shares64,250,000
Market Cap$10.94 billion

Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

How were Salix Pharmaceuticals' earnings last quarter?

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced its quarterly earnings results on Monday, March, 2nd. The specialty pharmaceutical company reported ($2.61) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $2.32. The specialty pharmaceutical company earned $13 million during the quarter, compared to the consensus estimate of $187.97 million. Salix Pharmaceuticals had a negative net margin of 2,134.34% and a negative return on equity of 305.24%. During the same period in the previous year, the business earned $1.06 earnings per share. View Salix Pharmaceuticals' Earnings History.

How do I buy shares of Salix Pharmaceuticals?

Shares of SLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Salix Pharmaceuticals' stock price today?

One share of SLXP stock can currently be purchased for approximately $172.81.

How big of a company is Salix Pharmaceuticals?

Salix Pharmaceuticals has a market capitalization of $10.94 billion.

What is Salix Pharmaceuticals' official website?

The official website for Salix Pharmaceuticals is http://www.salix.com.

How can I contact Salix Pharmaceuticals?

Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.


MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  343 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  646
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel